Читать книгу The SAGE Encyclopedia of Stem Cell Research - Группа авторов - Страница 414

Like the above, the use of stem cells in treating hematological cancer has been challenged by a high rate of rejection, infection, and graft failure. The use of pharmacological molecules in combination with stem cell transplantation has the potential to thwart these challenges and increase efficiency of the stem cell at the same time. For instance, preparative administration of rabbit antithymocyte globulin followed by cyclophosphamide, busulfan, and fludarabine before the stem cell transplant may help reduce the complications. There is a phase II trial currently investigating how well giving rabbit antithymocyte globulin together with a low intensity of cyclophosphamide, busulfan, or fludarabine before the transplantation of allogeneic peripheral blood stem cells will enhance engraftment of T-cells in patients with hematological cancer.

In most cases less than 50% of T-cell chimerism is achieved after stem cell transplant, hence the study will assess the percentage of patients in the study group that achieved up to 90% T-cell chimerism after one month of treatment with the above procedure. The overall safety, including transplant toxicity and tolerability of the drugs, and efficacy of the procedure will be assessed to determine the ability of the regimen to induce durable remissions in study patients. The study will monitor the incidence of chronic and acute graft-versus-host disease to determine how safe this procedure is in treating the patients.